 VANCOUVER, British Columbia, April 28, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company Nasdaq: INM; TSX:IN, a world leader in the clinical development of cannabinol CBN, today announced that it has filed Clinical Trial Applications CTAs in Austria, Israel and Serbia as part of a Phase 2 clinical trial of INM-755 cannabinol cream in Epidermolysis Bullosa EB. Additional CTAs for 755-201-EB the 201 study will be submitted to National Competent Authorities NCAs and Ethics Committees ECs in France, Germany, Greece, and Italy in the coming weeks. 